gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 23 Nov 2014.

Leucine-rich repeat kinase 2

LRRK2, leucine-rich repeat kinase 2, PARK8
This gene is a member of the leucine-rich repeat kinase family and encodes a protein with an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40 domain. The protein is present largely in the cytoplasm but also associates with the mitochondrial outer membrane. Mutations in this gene have been associated with Parkinson disease-8. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: AGE, E3 ubiquitin ligase, CAN, PINK1, DJ-1
Papers using LRRK2 antibodies
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.
Supplier
Lightowlers Bob, In PLoS ONE, 2009
... For LRRK2, rabbit monoclonal MJFF2 (Epitomics – see ...
LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease
Supplier
Kahle Philipp J., In PLoS ONE, 2009
... ReagentsAll cell culture media and supplements, BacMam LRRK2-GFP reagents, PrestoBlue™ cell viability assay reagent, Western blotting reagents and human neural stem cells were obtained from Life Technologies (Carlsbad, CA) ...
Aggregate formation and toxicity by wild-type and R621C synphilin-1 in the nigrostriatal system of mice using adenoviral vectors
Supplier
Xia Xu-Gang et al., In International Journal of Biological Sciences, 2008
... LRRK2 and tTA transgenic rats were produced by ...
Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein.
Supplier
Feany Mel B., In PLoS ONE, 2007
... Full length WT-LRRK2 pCMV6-XL5 was purchased from Origene (NM_198578.2) ...
Tyramine and octopamine independently inhibit serotonin-stimulated aversive behaviors in Caenorhabditis elegans through two novel amine receptors.
Supplier
Hart Anne C., In PLoS ONE, 2006
... driven WT or mutant LRRK2 constructs, were injected with the co-injection marker, promoter of nmr-1 driven YFP2 [55], into transgenic wild type nematode lines ...
more suppliers
Papers on LRRK2
Phosphorylation of CLIP-170 by LRRK1 regulates EGFR trafficking by promoting recruitment of p150Glued to MT plus-ends.
New
Hanafusa et al., In J Cell Sci, 20 Dec 2014
We have recently shown that LRRK1, which is related to the familial Parkinsonism gene product Park8/LRRK2, regulates this EGFR transport in a manner dependent on LRRK1 kinase activity.
Effects of sevoflurane on leucine-rich repeat kinase 2-associated Drosophila model of Parkinson's disease.
New
Xu et al., Guangzhou, China. In Mol Med Report, 18 Dec 2014
Leucine‑rich repeat kinase 2 (LRRK2) genetic mutations are the most common cause of familial PD, contributing to ~39% of all cases in certain populations.
Neural stem cells in Parkinson's disease: a role for neurogenesis defects in onset and progression.
New
Schwamborn et al., Esch-sur-Alzette, Luxembourg. In Cell Mol Life Sci, 18 Dec 2014
Indeed, animal models deficient in Nurr1, Pitx3, SNCA and PINK1 display deregulated embryonic neurogenesis and LRRK2 and VPS35 have been implicated in neuronal development-related processes such as Wnt/β-catenin signaling and neurite outgrowth.
Higher Frequency of Certain Cancers in LRRK2 G2019S Mutation Carriers With Parkinson Disease: A Pooled Analysis.
New
Saunders-Pullman et al., Tel Aviv-Yafo, Israel. In Jama Neurol, 17 Dec 2014
Importance: Patients with Parkinson disease (PD) who harbor LRRK2 G2019S mutations may have increased risks of nonskin cancers.
Clinical Correlations With Lewy Body Pathology in LRRK2-Related Parkinson Disease.
New
Marras et al., Toronto, Canada. In Jama Neurol, 17 Dec 2014
Importance: Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of genetic Parkinson disease (PD) known to date.
The Complex Relationships between Microglia, Alpha-Synuclein, and LRRK2 in Parkinson's Disease.
Review
New
LaVoie et al., Boston, United States. In Neuroscience, 01 Nov 2014
UNLABELLED: The proteins alpha-synuclein (αSyn) and LRRK2 are both key players in the pathogenesis of the neurodegenerative disorder Parkinson's disease (PD), but establishing a functional link between the two proteins has proven elusive.
LRRK2, a puzzling protein: Insights into Parkinson's disease pathogenesis.
Review
New
Cardoso et al., Coimbra, Portugal. In Exp Neurol, Jul 2014
UNLABELLED: Leucine-rich repeat kinase 2 (LRRK2) is a large, ubiquitous protein of unknown function.
Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease.
New
Impact
Dawson et al., Baltimore, United States. In Cell, May 2014
Mutations in leucine-rich repeat kinase 2 (LRRK2) are a common cause of familial and sporadic Parkinson's disease (PD).
Multiplying messages LRRK beneath Parkinson disease.
New
Impact
Guo et al., Ann Arbor, United States. In Cell, May 2014
link PD protein leucine-rich repeat kinase 2 (LRRK2) to abnormalities of translational control, a pathogenic mechanism implicated in an increasing number of CNS neurodegenerative diseases, as well as in normal aging.
Interaction of LRRK2 with kinase and GTPase signaling cascades.
Review
New
Wolozin et al., Boston, United States. In Front Mol Neurosci, Dec 2013
LRRK2 is a protein that interacts with a plethora of signaling molecules, but the complexity of LRRK2 function presents a challenge for understanding the role of LRRK2 in the pathophysiology of Parkinson's disease (PD).
Genetics and genomics of Parkinson's disease.
Review
New
Farrer et al., Vancouver, Canada. In Genome Med, Dec 2013
Recent discoveries in sporadic, Mendelian and more complex forms of parkinsonism provide novel insight into disease etiology; 28 genes, including those encoding alpha-synuclein (SNCA), leucine-rich repeat kinase 2 (LRRK2) and microtubule-associated protein tau (MAPT), have been linked and/or associated with PD.
Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis.
Review
New
Halliday et al., Australia. In Front Mol Neurosci, Dec 2013
Elevated phosphorylation of the PD-defining pathological protein, α-synuclein, correlates with its aggregation and toxic accumulation in neurons, whilst genetic missense mutations in the kinases PTEN-induced putative kinase 1 and leucine-rich repeat kinase 2, increase susceptibility to PD. Experimental evidence also links kinases of the phosphoinositide 3-kinase and mitogen-activated protein kinase signaling pathways, amongst others, to PD. Understanding how the levels or activities of these enzymes or their substrates change in brain tissue in relation to pathological states can provide insight into disease pathogenesis.
Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression.
New
Impact
Sterneckert et al., Germany. In Cell Stem Cell, Apr 2013
The LRRK2 mutation G2019S is the most common genetic cause of Parkinson's disease (PD).
Progressive degeneration of human neural stem cells caused by pathogenic LRRK2.
Impact
Izpisua Belmonte et al., Beijing, China. In Nature, 2012
We decided to evaluate nuclear organization in the context of ageing-associated disorders by focusing on a leucine-rich repeat kinase 2 (LRRK2) dominant mutation (G2019S; glycine-to-serine substitution at amino acid 2019), which is associated with familial and sporadic Parkinson's disease as well as impairment of adult neurogenesis in mice.
[The absence of the common LRRK2 G2019S mutation in 120 young onset Hungarian Parkinon's disease patients].
GeneRIF
Molnár et al., Budapest, Hungary. In Ideggyogy Sz, 2012
Data suggest that the mutation LRRK2 G2019S may be a rare cause of Parkinson disease in the Hungarian population.
Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations.
GeneRIF
Kortholt et al., Groningen, Netherlands. In Proc Natl Acad Sci U S A, 2012
data give important insight in the LRRK2 activation mechanism and, most importantly, explain the G2019S-related increase in LRRK2 kinase activity
Number and brightness analysis of LRRK2 oligomerization in live cells.
GeneRIF
Jameson et al., Honolulu, United States. In Biophys J, 2012
results show, for the first time to our knowledge, that LRRK2 is predominantly monomeric throughout the cytosol of living cells, but attains predominately higher oligomeric states in the plasma membrane
GST P1, a novel downstream regulator of LRRK2, G2019S-induced neuronal cell death.
GeneRIF
Chen et al., Shanghai, China. In Front Biosci (elite Ed), 2011
results suggest a previously undefined signaling mechanism underlying the neurotoxic effect of LRRK2 (G2019S), in which LRRK2 (G2019S) triggers oxidative stress in cells
Evaluation of the role of LRRK2 gene in Parkinson's disease in an East Indian cohort.
GeneRIF
Ray et al., Calcutta, India. In Dis Markers, 2011
LRRK2 has minimal role as a candidate and susceptibility gene in Parkinson's disease pathogenesis among East Indians.
Pathological roles of α-synuclein in neurological disorders.
Review
Impact
Stefanis et al., Athens, Greece. In Lancet Neurol, 2011
α-Synuclein also seems to be linked to other genetic forms of Parkinson's disease, such as those linked to mutations in GBA or LRRK2, possibly through common effects on autophagy and lysosomal function.
More papers using LRRK2 antibodies
Purification and characterization of Rac 2. A cytosolic GTP-binding protein that regulates human neutrophil NADPH oxidase.
Supplier
Kahle Philipp J., In PLoS ONE, 1991
... The DR4A/3EDD anti-LRRK2-kinase domain antibody is described in reference [35] and goat polyclonal anti 14-3-3 antibody was purchased from Santa Cruz (Santa Cruz Biotechnology, Santa Cruz, CA, USA) ...
share on facebooktweetadd +1mail to friends